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Abstract 
As a response to the 2011 National Patient Safety Goals (NPSG), a Coumadin Team, 
consisting of a Physician Chair, Pharmacists, and Registered Nurses, was formed at 
Mission Health System to focus on International Normalized Ratio (INR) testing, 
Coumadin dosing, and patient education.  The goal of this team has been to identify and 
eliminate barriers that prevent the stabilization of INRs within the prescribed goal range, 
and to ensure that all patients receive education about Coumadin therapy in order to 
prevent harm and reduce readmission rates related to Coumadin therapy.  The purpose of 
this study is to compare readmission rates within the same timeframe in consecutive 
years, before and after the Coumadin Team was initiated, to determine if these measures 
have in fact been an effective avenue to reaching the 2011 NPSG.  In a retrospective 
chart review 556 patients with active Coumadin orders from July 1 – July 31, 2010 were 
compared to 417 patients with active Coumadin orders from July 1 – July 31, 2011 to 
determine if readmission rates in the 90 days following hospitalization were in fact lower 
as a result of one-to-one Coumadin therapy education by a Registered Nurse.  Research 
results have confirmed that in 2010 Coumadin related readmissions occurred at a rate of 
7.2% of the total patient group, while in 2011 Coumadin related readmission occurred at 
a rate of 1.4% of the total patient group, giving a net reduction of Coumadin readmission 
rates of 5.8% after the initiation of the Coumadin Team. 
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Chapter I 
Introduction 
 Anticoagulant therapy can be a lifesaver for many patients with health problems 
ranging from atrial fibrillation, deep vein thrombosis, pulmonary embolism, and 
mechanical heart valve implants to more complicated and lifelong issues with genetic 
clotting disorders (U.S. Department of Veterans Affairs, 2009).  Patients now have the 
ability to live full and healthier lives – all while living with disease processes that would 
have led to loss of life at an early age, as recently as two generations ago.  Anticoagulant 
therapy, like many therapies, is a blessing but also a curse, if not managed properly.  
Anticoagulant medications are more likely to cause harm to patients than other therapies 
because of complex dosing issues related to lifestyle, prescription and over the counter 
medication interactions, and dietary restrictions (Joint Commission, 2010).  Literature 
reviews show that very little research has been done in this area, so research is vital if the 
National Patient Safety Goals (NPSG) are going to be met.  The requirements are 
defined, and now the best way to meet those requirements must be determined. 
Background 
Originally identified in 1939, and first used on human subjects in 1941 by the 
Mayo Clinic, Coumadin (warfarin) was not commonly used to treat the public until after 
it was used successfully to treat President Dwight D. Eisenhower after he suffered a heart 
attack in the mid-1950s (Ansell, Oertel, & Wittkowsky, 2005).  Since that time, 
Coumadin has become the predominant oral anticoagulant used in the United States and 
North America (Ansell et al., 2005).  Since those early beginnings, little else has been 
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discovered about this compound.  Instead, scientists have focused on the role of vitamin 
K in Coumadin therapy, as well as patient education.   
In 2010 the Joint Commission issued the 2011 National Patient Safety Goals and 
listed among them was the need for more effective patient education related to 
anticoagulant therapy.  NPSG.03.05.01 specifically defines the expectations for 
anticoagulant education in the following excerpt: 
To achieve better patient outcomes, patient education is a vital component of an 
anticoagulation therapy program.  Effective anticoagulation patient education 
includes face-to-face interaction with a trained professional who works closely 
with patients to be sure that they understand the risks involved with 
anticoagulation therapy, the precautions they need to take, and the need for 
regular International Normalized Ratio (INR) monitoring.  The use of 
standardized practices for anticoagulation therapy that include patient 
involvement can reduce the risk of adverse drug events associated with… 
warfarin (NPSG). 
Purpose 
 The purpose of this study is to determine if one-to-one education regarding 
Coumadin therapy performed by a Registered Nurse can increase post-hospitalization 
compliance.  With a therapeutic INR goal of 2.0-3.0 and an intense therapeutic INR goal 
of 2.5-3.5, it is imperative patients be compliant with their diet and laboratory testing 
schedules to prevent complications from sub-therapeutic or critically high INR levels 
(Barber, 2011).  Completion of this study will show that one-to-one education performed 
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by a Registered Nurse regarding Coumadin therapy can increase compliance and 
decrease readmission rates and sentinel events related to Coumadin therapy. 
Research Questions 
 The ultimate questions behind this research are two-fold.  First, will one-to-one 
Coumadin therapy education by a Registered Nurse be more relatable to the patient,  and 
therefore better understood?  Secondly, will patients be able to put that information to 
better use in relation to dietary compliance and adherence to INR testing schedules as 
dictated by their primary care provider?   
Hypothesis 
 The researcher hypothesizes this study will show that one-to-one Coumadin 
therapy education performed by a Registered Nurse can increase compliance and 
decrease readmission rates and sentinel events related to Coumadin therapy. 
Significance 
The significance of this research is evident in the fact that The Joint Commission 
(TJC) is requesting interventions to reduce patient morbidity and mortality related to 
anticoagulant therapy.  In addition to the dangers that Coumadin therapy can present for 
patients, adverse events also contribute to the increasing cost of healthcare for patients 
and the institutes that serve them.  Given an estimated inpatient cost of major 
anticoagulant-related bleeding of $7,500, Ansell et al. (2005) report that retained annual 
savings by preventing five major events would be $37,500 per 100 patients. 
The National Institutes of Health Drug-Nutrient Interaction Task Force (2003) 
reports the average intake of vitamin K for most adults in the U.S is 70 to 80 micrograms 
(mcg) daily.  The recommended daily value for vitamin K is 80 mcg, which is an estimate 
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of daily need (National Institute of Health, 2003).  Because vitamin K is a vital part in the 
creation of functioning prothrombin, it acts as an antidote to Coumadin (Ansell et al., 
2005).  It is therefore recommended that adults on Coumadin therapy limit the intake of 
vitamin K rich vegetables that provide more than 60% of the daily value for vitamin K 
(National Institute of Health, 2003). 
 The ultimate goal of this study is to ascertain whether or not one-to-one 
Coumadin therapy education provided by a Registered Nurse will result in lower 
readmission rates and decreased sentinel events related to Coumadin therapy.  While 
there is no completely accurate method of measuring compliance, Ansell et al. (2005) 
report that compliance issues with Coumadin therapy are the same as other disease 
processes, with the exception of the fear of bleeding.  Compliance must then be measured 
by the frequency of poor outcomes that are the result of non-compliance.  For Coumadin 
patients, poor outcomes are defined as those outcomes that lead to a major bleeding event 
or a newly diagnosed clotting disorder. 
Theoretical Framework 
Nola Pender’s Health Promotion Model (HPM) will be used as the theoretical 
framework for this study (see Figure 1).  The HPM acknowledges the cognitive-
perceptual factors and the modifying factors that can influence a patient’s participation in 
health-promoting behaviors.  Understanding patient barriers can assist the nurse in 
helping the patient to understand their own perceived barriers to action and boost their 
belief in their own perceived self-efficacy.  Ultimately patients will be away from health 
care facilities and must have a plan in effect to overcome their own barriers and to focus 
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on the perceived benefits of action that will result from optimal compliance (Tomey & 
Alligood, 2006). 
The HPM begins by acknowledging prior related behaviors that led to less than 
optimal outcomes for the patient.  Personal factors for the patient that encompasses 
biological, psychological, and sociocultural factors are then included as variables that 
may or may not be changeable.  Perceived benefits and barriers to action are then 
explored with the patient to determine the most effective plan to achieve compliance 
(Tomey & Alligood, 2006). 
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Figure 1.  Revised Health Promotion Model. (From Pender, N.J., Murdaugh, C.L. & Parsons, M.A. [2002], 
Health promotion in nursing practice [4
th
 ed., p. 60]. Upper Saddle River, NJ: Prentice-Hall. 
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 Table 1 and Table 2 identify how the concepts shown in the HPM will be utilized 
in the educational process to increase patient knowledge regarding Coumadin therapy, 
and which health promoting behaviors will be encouraged in the quest for compliance. 
Table 1 
Description of the Coumadin Education Plan Integrated with the HPM. 
BEHAVIOR SPECIFIC COGNITIONS AND AFFECT 
Perceived Benefits of Action INR within goal range for catalyst diagnosis 
Perceived Barriers of Action Knowledge deficit related to Vitamin K 
Lack of transportation for lab work 
 
Perceived Self-Efficacy 
 
Judgment of personal capability to limit 
Vitamin K intake, find solutions to 
transportation issues, and incorporate safety 
precautions into lifestyle 
 
Activity-Related Affect 
 
Subjective feelings, be they positive or 
negative surrounding the behaviors necessary 
to achieve goal INR, and work within a safe 
environment 
 
Interpersonal Influences 
 
Expectations of family or friends, level of 
social support, education provided, and 
modeling of other people living with 
Coumadin therapy 
 
Situational Influences 
 
Perceptions of options available, the 
demands that Coumadin therapy places on 
personal lifestyle, and the aesthetic features 
of the environment from which a patient 
must pursue health-promoting behaviors 
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Table 2 
Description of Behavioral Outcomes Based on Patient Controlled Events 
BEHAVIORAL OUTCOME 
Immediate competing demands (low 
control) and preferences (high control) 
Low Control – Timing of Coumadin 
administration, frequency of INR lab work, 
limiting Vitamin K in diet 
High Control – Diet choices with respect to 
types of foods available, time of 
evening/night to take Coumadin dose, where 
and how INR testing takes place 
 
Commitment to a plan of action 
 
Plan of action should be determined with the 
patient and their family (if requested), tools 
to support compliance should be available 
(such as dietary serving information, cost of 
Coumadin and pharmacy information, 
location of Coumadin clinics and style of 
testing [blood draw vs. finger stick]) 
  
In this study, Pender’s concept of interpersonal influences was synonymous with 
one-to-one education regarding Coumadin therapy.  This education will provide the best 
foundation for patients to begin to make the changes necessary to obtain all of the 
benefits of anticoagulant therapy, while minimizing the risks involved.  One-to-one 
education would include: (a) instructions on dosing of Coumadin, (b) INR testing and 
patient goals, (c) signs and symptoms of bleeding and/or blood clots, (d) tips to help 
prevent cuts and bleeding, (e) possible drug interactions, (f) Coumadin storage 
instructions, (g) dietary restrictions, and (h) vitamin and nutritional supplement 
precautions (Mission Hospital, 2010). 
 Pender’s concept of perceived self-efficacy was considered to be dietary 
compliance.  Dietary compliance was determined by confirmation by the patient that they 
have limited intake of foods high in vitamin K, limited cranberry and grapefruit juice to 
eight ounces daily, eliminated liver from their diet, avoided all herbal teas, and avoided 
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or limited soybeans and soy products from their diet (Mission Hospital, 2010).  This 
confirmation came via chart review to identify the presence of health promoting 
behaviors. 
 Pender’s concept of health promoting behavior was considered to be the absence 
of readmission within the first 90 days of hospital discharge for reasons related to 
Coumadin therapy.  According to Tomey and Alligood (2006), the movement to greater 
responsibility and accountability for successful personal health practices requires the 
support of the nursing profession through development of evidence-based practice, 
(p.462).  This study was performed to determine if the educational support of Registered 
Nurses could influence patient responsibility and accountability and therefore reduce 
readmission rates and sentinel events related to Coumadin therapy. 
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Chapter II 
Literature Review 
 The study of the effects of one-to-one patient education on Coumadin (warfarin) 
self-medication by a Registered Nurse has the potential to increase patient compliance 
and decrease readmission rates and sentinel events.  While this study measured 
readmission rates, many areas need to be evaluated to understand what these rates 
represent when patients are given standard educational materials.  The complexity of 
Coumadin therapy requires a broad review of patient compliance as it relates to 
medication dosing, INR monitoring, and dietary intake.  There is simply no one factor 
that often leads to an adverse event, but more of a series of factors that lead to a cascade 
effect that cause the adverse event.  This literature review looked at many of these areas 
in an attempt to isolate the education component in understanding patient compliance. 
Education and Health Literacy 
 A prospective, multicenter, open randomized study was performed by Pernod et 
al. (2008) to evaluate the effectiveness of an oral anticoagulation patient education 
program in reducing adverse events in Coumadin patients.  Both hemorrhagic and 
recurrent thrombotic complications were evaluated to determine the effectiveness of the 
educational program.  The sample included 302 patients, over the age of 18, diagnosed 
with deep vein thrombosis or pulmonary emboli requiring Coumadin therapy for a 
minimum of three months.  Research nurses, blinded to the study groups, interviewed the 
study sample 90 days after enrollment to identify episodes of bleeding and symptomatic 
recurrence of venous thromboembolism (Pernod et al., 2008) 
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 Participants either received standard care alone, or participated in a tailored 
educational intervention lasting 20-30 minutes.  These educational sessions consisted of a 
one-to-one teaching session.  Thrombotic or hemorrhagic complications were not shown 
to be decreased, as the results were similar to previous data.  The significant findings of 
this study were the fact that the educational intervention group did have a threefold 
reduction of adverse events.  The authors report that this “supports a significant and 
independent impact of our educational program on the reduction in risk of events” 
(Pernod et al., 2008). 
 Limited health literacy is but one of the factors that lead to difficulty following 
medication instructions, and can often lead to poor health outcomes.  Fang, Machtinger, 
Wang, and Schillinger (2006) conducted a study using bivariate analysis comparisons to 
determine the effect of limited health literacy on Coumadin knowledge, adherence, and 
control.  Medications that are known to be potentially dangerous require that patients’ 
understanding and participation during therapy are obtained (Fang et al., 2006). 
 During this study, patients were asked to complete a Test of Functional Health 
Literacy in Adults (s-TOFHLA) to determine their level of health literacy, and then to 
answer questions about their Coumadin therapy.  One hundred seventy-nine patients 
participated in this study, which ultimately determined that limited health literacy was not 
associated with missing Coumadin doses, but did correlate with incorrect answers on the 
mechanism of Coumadin, medication interactions, and frequency of monitoring.  Limited 
health literacy was not found to be associated with the percentage of time that a patient 
was in therapeutic INR range (Fang et al., 2006). 
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 St. Louis and  Robichaud-Ekstrand (2003) conducted a descriptive and 
correlational study to determine if knowledge level and coping strategies correlated with 
INR levels.  They report that anywhere from 20 to 70% of patients are non-compliant 
because of a lack of knowledge or an incorrect interpretation of physician instructions.  
Interestingly, they also report that Coumadin has been found to be one of the three 
medications for which geriatric patients are the least compliant.  Documented reasons for 
non-compliance include frequent blood tests, travel costs, diet modifications, and a belief 
that the treatment is useless (St. Louis & Robichaud-Ekstrand, 2003). 
 This study included 100 subjects and sought to answer two questions. The first 
was to identify the knowledge that older persons with atrial fibrillation had about 
anticoagulant therapy and the coping strategies they used.  The second was to establish 
relationships between knowledge level, coping strategies, and INR levels.  Researchers 
found a correlation between knowledge level and coping strategies, but coping strategies 
did not correlate to therapeutic INR levels (St. Louis & Robichaud-Ekstrand, 2003). 
Compliance and Perceived Barriers 
 Parker et al. (2007) performed a prospective cohort study to assess and quantify 
patient compliance of medication administration times.  This study used the electronic 
medication event monitoring system (MEMS) cap measurements to verify the claims of 
both self-report and clinician assessment of patient adherence.  One hundred  forty- five 
participants who were newly started on Coumadin (less than two months) were given 
MEMS caps for their warfarin pill bottles, which records the time and date the bottles 
were opened.  Results showed that patients may benefit from adherence counseling even 
when they claim to be taking their warfarin, as patient reported compliance and physician 
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assessment of compliance did not often correlate with the data retrieved from the MEMS 
caps.  The first six months of monitoring showed worsening compliance, which was 
followed by improvement beyond the six month date (Parker et al., 2007). 
 Woo, Chang, Ewing, and Bauer (2008) conducted research using secondary 
analysis of data from a prospective cohort study to determine if Coumadin use increased 
the risk of osteoporosis in older men.  Medications that cause further health 
complications can often result in non-compliance, as the patient may view that the risks 
outweighed the benefits of that medication therapy.  Bone mineral density at the hip and 
spine were used as a baseline for 5533 community dwelling ambulatory men.  Follow-up 
at 5.1 years found that the risk of non-spine fracture was similar in warfarin user and 
nonusers.  Final results found that warfarin use was not associated with lower bone 
mineral density, accelerated bone less, or higher non-spine fracture risk (Woo et al., 
2008). 
A qualitative study using a semi-structured group interview of 11 nurses of the 
Northern Sydney Area Health Service was performed by Bajorek, Krass, Ogle, Duguid, 
and Shenfield (2006) to explore the barriers to Coumadin use from the nursing 
perspective while working with geriatric patients.  Investigators reveal that Australian 
studies indicate that Coumadin therapy is underutilized in the geriatric population, even 
when contraindications are absent.  Lack of support services for elderly patients is cited 
as one of the reasons for this underutilization (Bajorek et al., 2006).   
Data from 11 nurses was collected during a group interview in order to assess the 
attitudes, feelings, beliefs, experiences, and reactions that nurses had in relation to 
Coumadin use.  Sessions were tape recorded and notes were also taken by a scribe to 
14 
 
 
 
ensure accuracy.  The researchers found that nurses are a potentially underutilized 
resource for prescribers and patients, which is unfortunate, as nurses maintain a unique 
relationship with patients (Bajorek et al., 2006). 
Safety and INR Monitoring 
 An open-label, three-treatment, randomized crossover clinical trial was conducted 
by Mohammed Abdul et al. (2008) to determine if cranberry or garlic intake would have 
a pharmacodynamic interaction with Coumadin.  Intake of either cranberry or garlic 
would result in patients appearing to have international normalized ratio (INR) levels that 
would indicate non-compliance.  A single 25mg dose of Coumadin was given to 12 
healthy males alone or after two weeks of pre-treatment with either cranberry or garlic.  
Both herbal medicines showed some evidence of VKORC1 genotype-dependent 
interactions with warfarin, which researchers noted is worthy of further investigation 
because this interaction indicates that the effects of Coumadin can be increased 
significantly as a result.  However, only cranberry was shown to increase the area under 
the INR time curve (by 30%).  Based on these results, the researchers recommended 
careful monitoring of the co-administration of cranberry and warfarin (Mohammed Abdul 
et al., 2008). 
 Lazo-Langer, Monkman, and Kovacs, (2009) performed a retrospective cohort 
study of consecutive ambulatory patients treated at a thrombosis clinic in a tertiary care 
hospital.  The purpose of the study was to determine if a model that incorporated genetic 
testing for determining warfarin dosing would be better than the nomogram currently in 
use.  It was thought that isolating genetic factors known to correlate with an individual’s 
clotting response would enable practitioners to achieve stable maintenance doses more 
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rapidly.  Three hundred and sixty-three outpatients with acute venous thromboembolism 
were started on treatment using a standardized Coumadin nomogram until stable, then 
linear regression was used to determine if the dosing requirements would have changed if 
genetic models were used. The researchers concluded that costly genetic testing was not 
necessary, and that maintenance Coumadin dosing can be accurately predicted using 
individual response to a standard warfarin initiation nomogram (Lazo-Langner et al., 
2009). 
 Researchers Rose, Ozonoff, Berlowitz, Henault, and Hylek (2009) conceded that 
many factors can contribute to suboptimal INR control: non-compliance with adherence 
to Coumadin therapy or dietary restrictions, interactions with other medications, and 
genetic differences between patient populations.  After exclusions of patients with INR 
target ranges other than 2.0-3.0 and patients new to warfarin, 3961 patients were chosen 
to participate in this observational study (Rose et al., 2009). 
INR levels showed that a shorter follow-up interval predicted a higher likelihood 
of dose change.  The study also showed that a dose change in one direction at a previous 
visit was predictive of a dose change in the opposite direction at the current visit.  This 
observational study suggests that warfarin dose changes when the INR is lower than 1.7 
or higher than 3.3 could improve control, as Coumadin dose changes any closer to the 2.0 
– 3.0 target range would ultimately result in a dose change in the opposite direction at the 
next visit.  Researchers also noted that this theory should be confirmed by a randomized 
trial (Rose et al., 2009). 
 In order to retain the benefits of Coumadin home treatment for deep vein 
thrombosis, researchers Harper, Monahan, and Baker, (2005) initiated a treatment 
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program that provided 5 mg of Coumadin for the first 6 days of treatment along with INR 
testing on day four and six.  Standard treatment consists of using a loading dose given 
over several days along with daily INR testing (Harper et al., 2005). 
 Using a retrospective audit after the induction of their low-dose Coumadin 
loading regimen, researchers evaluated 248 patients to determine if the new protocol was 
safe and effective.  The new treatment protocol also included the administration of low 
molecular weight heparin subcutaneously for at least five days.  Coumadin was given in 5 
mg doses daily with the first INR measurement taken on day four.  Daily INR 
measurements were then taken beginning on day six until the INR measurement reached 
2.0 or higher for two consecutive measurements (Harper et al., 2005). 
 While this method of low dose Coumadin initiation was deemed safe by the 
researchers due to the fact that of the 248 patients only eight had an INR greater than 3.0 
on day four, and only one had an INR greater than 4.0 on day four; it is noted that it does 
take longer for patients to reach the therapeutic level of 2.0 to 3.0.  This extended time for 
reaching therapeutic levels means that patients will need to take subcutaneous low 
molecular weight heparin longer, as most patients required six to ten days to reach a 
stable INR (Harper et al., 2005). 
 As more patients enter the healthcare market, researchers are trying to find ways 
to meet the needs of these populations by determining if expanding the developing role of 
nurses can meet those needs.  Connor, Wright, and Fegan, (2002) conducted a 
nonexperimental design study to determine if nurse-led anticoagulation services would be 
as safe and as effective as those led by hematologists.  Effectiveness was defined as 
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maintaining a patient between their INR target ranges for 70% of their visits (Connor et 
al., 2002). 
 Using a retrospective chart review, data was collected from patients who had 
undergone 18 months of continuous management from the hematologist consultants 
versus those who had undergone 18 months of continuous management by nurses.  The 
sample of patients consisted of 197 patients from 27 to 91 years of age.  Results indicated 
that that the anticoagulant nurses are equally as safe as the consultant hematologist in 
managing the anticoagulant therapy of clinic patients (Connor et al., 2002). 
 This study, like the previous one, was designed to test the effectiveness of a 
nurse-led anticoagulation service.  What makes this one unique is that the researchers are 
testing this theory in England, where patients had been traveling to their local hospital for 
testing.  This new service not only uses nurses, but does so in clinics that are located in 
local areas or using home health nurses.  The nurses are also utilizing a computer based 
decision support system, which was not being used by hospital doctors (Lusignan, 
Singleton, & Wells, 2004). 
 While patients overall liked the service because of the greater ease of testing, the 
computerized decision support system proved to be challenging.  Eighteen nurses 
participated in this program, all of whom were experienced in anticoagulation 
monitoring.  The difficulty lay in situations where the computer program recommended a 
particular dose and retesting date that the nurse did not agree with.  Because of these 
complications, nurses were reporting as never giving more Coumadin than recommended, 
but they did show an increased rate of arranging follow-up dates sooner than the program 
recommended.  Overall, the nurses operated on the side of caution.  The researchers 
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concluded that while the nurses acted cautiously, technological solutions based on 
hospital practice are difficult to implement in primary care (Lusignan et al., 2004). 
 Researchers Rose, Ozonoff, Henault, and Hylek (2008) performed a study in 
order to describe the management of patients with atrial fibrillation in the community 
based setting. The effectiveness of lower INR target ranges (1.5-2.5) and (2.0-2.5), 
intended to prevent bleeding risk, were questioned in relation to their effectiveness of 
preventing stroke.  Previous studies were reported that had suggested that lower INR 
levels may increase the risk of stroke without actually reducing bleeding risk.  In this 
community based study of 3396 patients from 101 community based practices, the 
reports of hemorrhage and stroke were low, but the risk versus benefit of lower INR 
ranges remains uncertain.  It is interesting to note that patients who had lower INR target 
ranges had more incidences of thromboembolic events and hemorrhagic events (Rose et 
al., 2008). 
Along with education, the second component that the Coumadin Team addresses 
is the necessary follow-up that patients require upon discharge.  The requirement set forth 
by the team dictates that patients must have a follow-up INR check within 48-72 hours of 
discharge.  Research completed by Jackson, Peterson, Vial, and Jupe (2004) also 
addresses this component and gives insight into the validity and efficacy of this practice. 
 A total of 128 patients were studied after they had been initiated on Coumadin in 
the hospital.  The group was randomly divided into two smaller groups, one of which 
received the usual care Coumadin patients had been receiving, which consisted of not 
only the usual care that their general practitioner would provide but also a visit from a 
pharmacist on day eight of therapy.  Their general practitioner was also contacted after 
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this visit to alert them if an adverse trend was identified or if the patients INR was not in 
the therapeutic range that was expected (Jackson et al., 2004). 
 The second group, known as the home care group, received home visits by a 
pharmacist on four occasions, beginning on the second day after discharge.  In addition to 
earlier INR checks by this pharmacist, the patients also received education at that first 
visit, consisting of information about anticoagulant therapy, possible adverse events, and 
medication interactions (Jackson et al., 2004). 
 This study reflects an increase in positive outcomes within the home care group.  
While both groups showed nearly the same percentage of patients had therapeutic INRs 
at discharge, by day number eight, only 4% of the home care group proved to have a 
supratherapeutic INR compared to 26% of the usual care group.  In addition, when 
compared at the three month mark, only 15% of the home care group had sustained a 
bleeding event, while 36% of the usual care group had sustained such an event.  This 
study shows a marked level of improvement in patient care and safety for the home care 
group (Jackson et al., 2004). 
Sampling Quality 
 The aim of this cross-section comparison study, conducted by researchers Zengin 
and Enc (2006), was to determine if concurrent blood samples taken from venipuncture 
and via peripheral venous catheter showed a clinically significant difference in 
prothrombin time (PT) and activated partial thromboplastin time (aPTT) in patients 
currently undergoing anticoagulant therapy.  While the traditional method for testing 
Coumadin effectiveness is the INR, many hospitals utilize the PT/INR which does fall 
under the scope of this testing (Zengin & Enc, 2006). 
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 A sample population was taken of 120 patients who were undergoing 
anticoagulation therapy, while patients who were undergoing thrombolytic therapy were 
excluded.  Each type of blood sample was drawn simultaneously from the patient.  Blood 
collected via venipuncture was labeled as the reference sample, while blood from the 
peripheral venous catheter was labeled as the experimental sample.  This method allowed 
each case to serve as their own control.  The results of this study ultimately concluded 
that it is safe practice to collect blood sample from peripheral venous catheters for use in 
PT and aPTT testing (Zengin & Enc, 2006). 
 Throughout the literature, many areas have been studied in order to ascertain the 
precise reason for adverse reactions and sentinel events related to Coumadin therapy.  
The key behind all of these studies would, by all accounts, be linked to the lack of patient 
knowledge regarding their therapy.  This common link is evident behind the 
NPSG.03.05.01 requirements as reiterated below: 
To achieve better patient outcomes, patient education is a vital component of an 
anticoagulation therapy program.  Effective anticoagulation patient education 
includes face-to-face interaction with a trained professional who works closely 
with patients to be sure that they understand the risks involved with 
anticoagulation therapy, the precautions they need to take, and the need for 
regular International Normalized Ratio (INR) monitoring.  The use of 
standardized practices for anticoagulation therapy that include patient 
involvement can reduce the risk of adverse drug events associated with…warfarin 
(NPSG). 
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 The strengths of the research contained in this literature review are the various 
ways that researchers are attempting to isolate the components that lead to readmissions 
and sentinel events related to Coumadin therapy.  Like working through a maze, the 
correct path can only be discovered by revealing the failures of the other paths available.  
Literature review has then outlined that genetic testing, reduced INR goals, and low dose 
Coumadin initiation are not valid paths to reducing readmission rates and sentinel events 
related to Coumadin therapy. 
Conclusion 
 This literature review found many studies on the various types of barriers to 
effective INR goals, however, specific studies to determine if one-to-one education by a 
Registered Nurse would result in increased compliance and decreased readmission rates, 
and sentinel events were scarce to non-existent.  By all appearances, this is an area with a 
need for research in the future. 
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Chapter III 
Methodology 
With a therapeutic International Normalized Ratio (INR) goal of 2-3, and an 
intense therapeutic INR goal of 2.5-3.5, it is imperative that patients be compliant with 
their diet and laboratory testing schedules to prevent complications from sub-therapeutic 
or critically high INR levels.  The purpose of this research study was to ascertain whether 
or not one-to-one education by a Registered Nurse about Coumadin (warfarin) therapy 
could increase compliance and decrease readmission rates and sentinel events related to 
Coumadin therapy (Barber, 2011). 
Implementation 
 Quantitative data was obtained using a retrospective chart review process.  Each 
patient record was reviewed to determine if the patient was new to Coumadin or 
continuing Coumadin therapy, what the diagnostic catalyst was for the initiation of 
Coumadin therapy, and whether or not they had been readmitted to the hospital within 90 
days of the research period.  It was also determined if the readmissions were related or 
unrelated to their Coumadin therapy. Specifically, readmissions related to Coumadin 
therapy would include all cases where patients were admitted because of bleeding, and/or 
cases where the patient was diagnosed with any form of a blood clot. 
Setting 
This research was conducted at a hospital in the Southeastern United States.  This 
health care facility is a designated Level II Trauma Center with over 800 inpatient beds.  
Patient care units selected for this study were diverse, including Medical Surgical Units, 
Progressive Care Units, Intensive Care Units, and Psychiatric Care Units.  Emergency 
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Care, Labor and Delivery, Pediatrics, and 24 hour observation units were not included in 
the study setting. 
Sample 
Patient samples were obtained from the information technology department at the 
health care facility.  A total of 973 patients with active Coumadin orders were selected 
for this study.  The pre-intervention group consisted of 556 patients which were selected 
from July 1, 2010 to July 31, 2010.  The pre-intervention group were all patients at the 
facility before the initiation of the Coumadin Team.  The post-intervention group 
consisted of 417 patients which were selected from July 1, 2011 to July 31, 2011.  The 
post-intervention group was all patients at the facility after the initiation of the Coumadin 
Team.  Due to the strict dietary requirements to maintain a stable INR, it was felt that 
testing groups from consecutive years during the same month would eliminate variations 
that could potentially exist simply because of the unavailability of some green leafy 
vegetables in the other months. 
All patients selected for both groups were receiving Coumadin therapy for a 
history of deep vein thrombosis, pulmonary emboli, orthopedic surgery, atrial fibrillation, 
atrial flutter, heart valve disease or replacement, cardiovascular disease, cerebrovascular 
disease, factor V Leiden deficiencies, port-a-cath placement, or other diagnostic catalyst 
as defined by their physician.   
Research Design 
A quasi-experimental design has been chosen to complete a retrospective chart 
review for 973 patients within the selected healthcare facility. Comparisons looked at the 
readmission rates of 556 Coumadin patients from July 1, 2010 to July 31, 2010, who 
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were admitted before their Coumadin Team was formed, and 417 patients from July 1, 
2011 to July 31, 2011, who were admitted after their Coumadin Team was formed in 
January 2011.  The purpose of using a quasi-experimental research design is to examine 
the cause-and-effect relationship between one-to-one Coumadin education provided by a 
Registered Nurse and patient compliance (Burns & Grove, 2009). 
Protection of Human Subjects 
Prior to conducting the chart reviews, the researcher obtained permission from the 
Internal Review Board (IRB) for Gardner-Webb University in Boiling Springs, NC as 
well as from the IRB for a Level II Trauma health care facility in the Southeastern United 
States.  As this study consisted of a retrospective chart review, informed consent was 
waived by the Gardner-Webb University IRB, as well as the health care facility’s IRB. 
Instruments 
 A data collection tool was used by the researcher to organize data obtained from 
the retrospective chart review (Appendix A).  This tool was designed to record the 
implementation status of the patients Coumadin therapy, the diagnostic catalyst for that 
therapy, and their readmission dates in the 90 days following their original admission.  
The tool also recorded the number of Coumadin related readmissions, as well as the 
unrelated readmissions during that same time period. 
Data Collection 
Data collected from the participants included their original admission date, and 
whether or not they were already taking Coumadin upon admission, or were prescribed 
Coumadin for the first time.  Data regarding their diagnostic catalyst for Coumadin, if 
they were readmitted within 90 days of the original admission, and whether or not the 
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diagnosis given to them during that admission was related in any way to their Coumadin 
therapy was also obtained. 
Data Analysis 
 All data, including statistical data, was entered into the Statistical Software for the 
Social Sciences, version 20 (SPSS v. 20, 2010) as well as into Microsoft Excel 2010.  
From these software platforms, the researcher was able to compare the percentage of 
occasions that each participant was readmitted to the hospital within the 90 day period 
following their original admittance.  The researcher was also able to compare the 
occurrence rates of the diagnostic catalysts which prompted the physician order for 
Coumadin therapy. 
Summary 
 The need for patient education regarding Coumadin therapy is clearly needed in 
order to ensure patient safety.  This research project was designed to ascertain the 
effectiveness of Coumadin education when provided on a one-to-one basis by a 
Registered Nurse.  All processes in this research project were designed to eliminate 
variances that have the potential to skew the results, such as performing data collection in 
the same month of the year for two consecutive years.  This eliminated variations that 
may occur due to the decreased availability of fresh vegetables in the winter months.  
Data was also eliminated from surgeons known to prescribe Coumadin for their patients 
while they were in the hospital, but discontinued it in favor of aspirin upon discharge.  
The ultimate goal was to determine the effectiveness of the Coumadin Team educational 
process. 
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Chapter IV 
Results 
This research project had a clear goal.  With a therapeutic International 
Normalized Ratio (INR) goal of 2-3, and an intense therapeutic INR goal of 2.5-3.5, it is 
imperative that patients be compliant with their diet and laboratory testing schedules to 
prevent complications from sub-therapeutic or critically high INR levels.  Once 
completed, this study will ascertain whether or not one-to-one education by a Registered 
Nurse about Coumadin (warfarin) therapy can increase compliance and decrease 
readmission rates, and sentinel events related to Coumadin therapy (Barber, 2011). 
Sample Characteristics 
 Two different samples were clearly defined in order to ascertain the effectiveness 
of patient education as it relates to Coumadin therapy at the chosen healthcare facility.  
The pre-intervention group was a total of 556 patients that had active Coumadin orders 
between July 1 and July 31 of 2010.  This sample was taken before the initiation of the 
Coumadin Team.  The post-intervention group was a total of 417 patients that had active 
Coumadin (warfarin) orders between July 1 and July 31 of 2011.  This sample was taken 
after the initiation of the Coumadin Team. 
 The pre-intervention group from 2010 had 556 total patients; 234 patients who 
were new to Coumadin therapy and 322 patients who were continuing Coumadin therapy 
during their admission.  The post-intervention group from 2011 had 417 total patients; 
197 who were new to Coumadin therapy and 220 who were continuing Coumadin 
therapy during their admission.  The numbers of patients which fell in each diagnostic 
category are outlined in Table 3. 
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Table 3 
Patient Diagnosis Rates by Year 
 July 1 – July 31, 2010 July 1 – July 31, 2011 
Treatment or secondary prevention of 
venous thromboembolism or 
pulmonary emboli 
107 64 
 
Prophylaxis of thromboembolism 
associated with surgery or trauma 
111 118 
 
Prophylaxis of thromboembolism 
associated with atrial fibrillation or 
flutter 
210 141 
 
Prophylaxis of thromboembolism 
associated with valvular heart disease 
or prosthetic heart valves 
41 16 
 
Prophylaxis of thromboembolism 
associated with heart disease 
21 13 
 
Prophylaxis of thromboembolism 
associated with cerebrovascular 
disease 
15 8 
 
Treatment of heparin-induced 
thrombocytopenia 
0 1 
 
Diagnosis of Factor V Leiden 
1 1 
 
Protein C or S deficiency 
0 0 
 
Antiphospholipid antibody syndrome 
1 0 
 
Other Diagnosis requiring Coumadin 
therapy 
17 8 
 
Treatment for multiple diagnoses 
requiring Coumadin therapy 
32 47 
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 The last data collected during this process was the number of readmissions each 
patient had in the 90 days following their initial admission within the defined dates.  
Once a readmission was found, it was then researched to discover if the readmission was 
related to the patient’s Coumadin therapy, or unrelated to their Coumadin therapy. The 
diagnoses that were  considered as related to Coumadin therapy, include any new type of 
blood clot, which included but were not limited to: (a)deep vein thrombosis, 
(b)pulmonary embolism, and (c) stroke due to emboli, as well as any type of bleeding 
disorder, which included but were not limited to: (a)gastrointestinal bleeding and (b) 
hemorrhagic stroke.  
 The number of readmissions related to Coumadin therapy in the 2010 group was 
40, while the number of readmissions unrelated to Coumadin therapy was 135.  The 
number of readmissions related to Coumadin therapy in the 2011 group was 6, while the 
number of readmissions unrelated to Coumadin therapy was 121.  The major findings of 
these results will be discussed in Chapter V.  Visual representations of the sample 
statistics can be found in Figures 2 through 4. 
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Figure 2. Patients Numbers by Sample Year 
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Figure 3. Rates of Coumadin Therapy Catalyst Diagnoses per Year 
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Figure 4.  Readmission Rates per Year 
Major Findings 
 In 2010 Coumadin related readmissions were 7.2% of the total number of 
patients, while in 2011 Coumadin related readmissions were 1.4% of the total number of 
patients.  This represents a reduction in Coumadin related readmissions of 5.8% from 
2010 (pre-intervention) to 2011 (post-intervention). 
 When the total number of readmissions versus the total number of patients from 
the 2010 and the 2011 post-intervention group were compared, the significance in a two-
tailed T test showed a p value of 0.072 which when divided showed a one tail p value of 
0.036, (See Table 4-6). 
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Table 4 
Paired Sample Statistics for the Pre and Post-Intervention Groups (Coumadin Related) 
 
 
Table 5 
Paired Samples Correlations for the Pre and Post-Intervention Groups (Coumadin 
Related) 
Paired Samples Correlations 
 
N Correlation 
 
Sig. 
 
    
Pair 1 
Total Number of Admissions & 
Number of Coumadin Related 
Readmissions 
     2 1.000 .000 
  
 
 
 
Paired Samples Statistics 
  
Mean 
 
N 
 
Std. Deviation 
 
Std. Error Mean 
 
Pair 1 
 
Total Number of 
Admissions 
 
486.50 
 
2 
 
98.288 
 
69.500 
Number of Coumadin 
Related Readmissions 
23.00 2 24.042 17.000 
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Table 6 
Paired Samples Test for the Pre and Post-Intervention Groups (Coumadin Related) 
 
 
 
 
 
 
 
 
 
 
Paired Samples Test 
 Paired Differences t df Sig. (2-
tailed) Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 
1 
Total Number of 
Admissions - 
Number of 
Coumadin Related 
Readmissions 
463.50
0 
74.246 52.500 -203.576 1130.576 8.829 1 .072 
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The two groups were also compared for readmission unrelated to Coumadin 
therapy.  This two-tailed T test had a p value of 0.055, (See Table 7-9). 
 
Table 7 
Paired Sample Statistics for the Pre and Post-Intervention Groups (Coumadin Unrelated) 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 
Total Number of Admissions 486.50 2 98.288 69.500 
Number of Unrelated 
Admissions 
128.00 2 9.899 7.000 
 
 
 
Table 8 
Paired Samples Correlations for the Pre and Post-Intervention Groups (Coumadin 
Unrelated) 
Paired Samples Correlations 
 N Correlation Sig. 
    
Pair 1 
Total Number of Admissions & 
Number of Unrelated 
Admissions 
2 1.000 .000 
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Table 9 
Paired Samples Test for the Pre and Post-Intervention Groups (Coumadin Unrelated) 
 
 
 This study found a 5.8% decrease in readmission rates between the pre-
intervention group in 2010 and the post-intervention group in 2011.  It also produced a 
one-tail p value of 0.036.  In multivariate analysis statistical significance was obtainable 
if p < 0.05. 
 
 
 
 
 
 
 
Paired Samples Test 
 
 Paired Differences t df Sig. (2-
tailed) Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 
1 
Total Number of 
Admissions - 
Number of 
Unrelated 
Admissions 
358.50
0 
88.388 62.500 -435.638 1152.638 5.736 1 .110 
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Chapter V 
Discussion 
 The most important task for any new team within the hospital setting must be to 
do what it set out to do, and to prove those measures are working with research and 
quantifiable data.  This research study was set forth to do just that.  The purpose of this 
research study was to look at the work being done, and ascertain whether or not 
Coumadin (warfarin) therapy education by a Registered Nurse was in fact reducing 
readmission rates. 
Implications of Findings 
 In 2010 Coumadin related readmissions were 7.2% of the total number of 
patients, while in 2011 Coumadin related readmissions were 1.4% of the total number of 
patients.  This represents a reduction in Coumadin related readmissions of 5.8% from 
2010 (pre-intervention) to 2011 (post-intervention).  The implications of these findings 
are profound.  A 5.8% reduction in the number of Coumadin related admissions in a 
single month translate to more than just numbers.  It translates into greater patient safety 
and a reduction in health care expenditures for the individual as well as the facility. 
 Descriptive statistics revealed that when the total number of readmissions versus 
the total number of patients from the 2010 and the 2011 post-intervention group were 
compared, the significance in a two-tailed T test showed a p value of 0.072, which when 
divided showed a one tail p value of 0.036.  Therefore the data shows that the reduction is 
statistically significant because p < 0.05, (See Tables 4-6). 
The second set of descriptive statistics for the unrelated readmissions is further 
proof that the decrease in readmission rates were related to the Coumadin education 
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provided to patients and not because of other factors.  If other factors were influencing 
readmission rates, then the unrelated rates should have also proven to be statistically 
significant and they were not.  This two-tailed T test did not show statistical significance 
as p = 0.055, which is higher than the statistically significant value of p < 0.05, (See 
Tables 7-9). 
 As previously stated, Ansell et al., 2005) reported that the average cost for 
readmission related to Coumadin therapy was $7,500, and that if one uses the average 
cost, then the reduction of readmissions by five events then translated into $37,500 saved 
in healthcare expenditures.  This study saw a reduction in Coumadin related readmissions 
of 34 events in a single month.  This translates into a total savings of $255,000 in 
healthcare expenditures.  This benefits not only the patient, but also the healthcare 
facilities which serve them. 
Application to Theoretical Framework 
 The application to Nola Pender’s Health Promotion Model (HPM) was 
appropriate for this study because it outlines the partnership that must take place between 
patient and care provider to achieve an optimal outcome.  Through education, the 
Registered Nurse can help patients to understand which factors they can control, and 
which factors they cannot control.  Perceived benefits and barriers to actions can then be 
explored together as a team to produce an environment with greater safety and control. 
 By understanding that dietary compliance and proper INR monitoring can vastly 
affect their own outcomes in relation to morbidity and mortality; patients can come to 
understand that they hold the key to a safe and happy future.  With the proper education, 
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patients then feel more equipped to handle Coumadin therapy and adjust their lifestyles to 
achieve the best outcomes. 
Limitations 
 Limitations were largely removed at the onset of this research project by careful 
planning; however there was one specific limitation that was beyond the researcher’s 
control.  This limitation is that several patients had been prescribed Coumadin therapy, 
but no clear indication could be found in the history and physical as to why.  On more 
than one chart, the hospitalist assigned to the patient, specifically noted in the history and 
physical that neither they nor the patient knew why they were taking Coumadin. 
Implications for Nursing 
 The implication for nursing is clear.  Even if the facility, where the nurse is 
employed, does not have a team dedicated to patient education about Coumadin, nurses 
must find a way to ensure that patients receive Coumadin education before discharge, and 
ensure that patients have a follow-up INR appointment at discharge.  This research 
further confirms that the 2011 NPSG are valid, and that complying with those goals does 
increase patient safety. 
Conclusion 
 In 1933, when a Wisconsin farmer named Ed Carlson brought a milk bottle full of 
cows blood that would not coagulate to researchers at the University of Wisconsin-
Madison’s Wisconsin Alumni Research Foundation (WARF) to find out why his cows 
had been dying after eating spoiled sweet clover, no one could have expected that the 
research that came out of this discovery would become the most widely prescribed blood 
thinner in the world.  Warfarin (trademarked Coumadin) took its’ name from these 
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modest beginnings at WARF, and is truly a miracle drug to the thousands whose lives it 
has saved (Jordan, 2011).  It is not, however, a drug to be taken lightly.  With frequent 
lab work to be completed, and a list of dietary and other drug interactions, patients must 
be presented with the best education possible so that they may pursue therapy while 
minimizing the risks of the harmful and potentially fatal side effects of this medication. 
One-to-one education provided by a Registered Nurse about Coumadin therapy 
can increase compliance and decrease readmission rates and sentinel events related to 
Coumadin therapy.  Patient education must become the cornerstone of any medication 
therapy regimen to provide the best outcome for our patients. 
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Target period admit date:
This patient was initiated on therapy during this hospitalization
This patient was receiving warfarin prior to admission, and therapy is being continued 
during hospitalization.
Indication for warfarin:
Treatment or secondary prevention of venousthromboembolism or pulmonary embolism
Prophylaxis of thromboembolism associated with surgery or trauma
Prophylaxis of thromboembolism associated with atrial fibrillation/flutter
Prophylaxis of thromboembolism associated with valvular heart disease or prosthetic heart valves
Prophylaxis of thromboembolism associated with cardiovascular disease
Prophylaxis of thromboembolism associated with cerebrovascular disease
Treatment of heparin-induced thrombocytopenia
Factor V Leiden
Protein C or protein S deficiency
Antiphospholipid antibody syndrome
Other:
Readmission Date: Admit diagnosis: Coumadin Related?
# Coumadin related readmissions
# Non-related readmissions
